2sev­en­ty bio stock drops 24% as com­pe­ti­tion catch­es up with BMS-part­nered mul­ti­ple myelo­ma drug

Com­pet­i­tive pres­sure and a pause in man­u­fac­tur­ing due to rou­tine main­te­nance have pushed US sales of Abec­ma (ide­cab­ta­gene vi­cleu­cel), Bris­tol My­ers Squibb and 2sev­en­ty bio’s CAR-T cell ther­a­py for mul­ti­ple myelo­ma, to new lows, caus­ing BMS to miss Wall Street’s quar­ter­ly ex­pec­ta­tions by about $40 mil­lion and 2sev­en­ty’s stock $TSVT to drop by 24% in af­ter­noon trad­ing.

The an­nounce­ment from Bris­tol My­ers, which equal­ly shares Abec­ma with 2sev­en­ty­bio, on lack­lus­ter sales pushed 2sev­en­ty — which does not an­nounce its quar­ter­ly re­sults un­til Nov. 14 — to re­lease an SEC fil­ing to­day mak­ing clear that com­pet­i­tive dy­nam­ics im­pact­ing Abec­ma are here to stay, and “will con­tin­ue in­to the fourth quar­ter of 2023.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER